{"entity":{"id":"nct07469774","kind":"trial","name":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Biocity Biopharmaceutics Co., Ltd., now recruiting.","summary":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07469774 by Biocity Biopharmaceutics Co., Ltd., with 111 participants planned, started 2026-03-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: BC3195 and Pembrolizumab/KEYTRUDA®.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07469774","url":"https://clinicaltrials.gov/study/NCT07469774"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07469774","phase":"1/2","setting":"A Phase 1/2, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","sponsor":"Biocity Biopharmaceutics Co., Ltd.","enrolled":111,"outcomes":[]},"route":"/trials/nct07469774/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}